Welcome to our dedicated page for Orthopedia SEC filings (Ticker: KIDS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The OrthoPediatrics Corp. (NASDAQ: KIDS) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. OrthoPediatrics is a Delaware-incorporated orthopedic medical device company focused on pediatric orthopedics, and its filings offer detailed information on its financial condition, operations, and governance.
Investors can review current reports on Form 8-K, where OrthoPediatrics reports material events such as quarterly earnings releases, preliminary unaudited revenue updates, revisions to financial guidance, and presentations to investors and analysts. The company also uses Form 8-K to disclose board changes, including director retirements and new appointments, and to furnish press releases related to business developments like OPSB expansion.
In addition to 8-Ks, OrthoPediatrics files periodic reports such as Form 10-Q and Form 10-K, which contain unaudited and audited financial statements, segment information, and risk factor discussions referenced in its news releases. These documents provide context on revenue by category (trauma and deformity, scoliosis, sports medicine/other procedures, and specialty bracing), operating expenses, restructuring charges, intangible asset impairments, and non-GAAP measures such as adjusted EBITDA.
Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy documents, helping readers quickly understand changes in guidance, major cost items, and business drivers. Users can also track real-time updates as new filings are posted to EDGAR, including any future Forms 4 reporting insider transactions, proxy statements detailing director compensation, and other governance-related documents. This centralized view of KIDS filings allows investors, analysts, and researchers to examine OrthoPediatrics’ regulatory history, financial disclosures, and corporate actions in one place, supported by AI-generated explanations that clarify complex sections of the filings.
Orthopedics Corp (KIDS) disclosed that it has prepared preliminary net revenue estimates but these figures are subject to completion of the company's audit and may change. The company warns that results for the third quarter and for the full year could differ materially from the preliminary estimates and cautions readers not to place undue reliance on forward-looking statements. Investors are directed to the Risk Factors discussion in the company's Annual Report filed with the SEC for factors that could cause actual results to diverge. The company also states it will not update these forward-looking estimates publicly unless required by law.
OrthoPediatrics Corp. (KIDS) Form 4: Chief Operating Officer and Chief Financial Officer Fred Hite purchased 5,076 shares of OrthoPediatrics common stock in the open market on 08/21/2025 at $19.41 per share, bringing his beneficial ownership to 213,065 shares including 150,360 restricted shares. The filing notes the purchase was matchable under Section 16(b) with a prior sale, and Mr. Hite disgorged $27,664.20 to the company representing the full short-swing profit.
The transaction was reported by an attorney-in-fact on 08/25/2025. The Form 4 shows direct ownership and does not report derivative transactions. No additional executive departures, changes in compensation, or forward-looking statements are included in the filing.
OrthoPediatrics announced the Board accepted the resignation of director Terry Schlotterback due to retirement, effective August 8, 2025; the filing states the departure was not due to any disagreement with the Company. The Board appointed Kelly Fischer to fill the vacancy and to serve in the director class expiring at the annual stockholder meeting in 2026. Ms. Fischer has been Senior Vice President and Chief Financial Officer of Cook Medical since 2003 and will join the Board's Audit Committee and Compensation Committee.
For her service, Ms. Fischer will be eligible to receive a pro rata portion of the 2025 Award under the Company's Non-Employee Director Compensation Policy (described in Exhibit 10.1 to a recent Quarterly Report). The Board also agreed that the remaining 10,900 unvested restricted shares previously granted to Mr. Schlotterback will remain outstanding and continue to vest on their scheduled timelines as though he remained a director. The company disclosed no material plans, contracts or related-party transactions involving Ms. Fischer.